Thomas Perwein

Thomas Perwein

Auto-generated profile, based on publicly available information

Thomas Perwein

Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz , Graz

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2020 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
TPThomas Perwein
Thomas Perwein
MBMartin Benesch
Martin Benesch
DKDaniela Kandels
Daniela Kandels
TPTorsten Pietsch
Torsten Pietsch
RSRené Schmidt
René Schmidt
AGAstrid K. Gnekow
Astrid K. Gnekow
Knowledge on management of pediatric spinal cord low-grade glioma (LGG) is scarce. We analyzed clinical datasets of 128 pediatric patients with spinal LGG followed within the prospective multicenter trials HIT-LGG 1996 (n = 36), SIOP-LGG 2004 (n = 56), and the subsequent LGG-Interim registry (n = 36). Spinal LGG, predominantly pilocytic astrocytomas (76%), harbored KIAA1549-BRAF fusion in 14/35 patients (40%) and FGFR1-TACC1 fusion in 3/26 patients (12%), as well as BRAFV600E mutation in 2/66 patients (3%). 10-year overall survival (OS) and event-free survival (EFS) was 93% ± 2% and 38% ± 5%, respectively. Disseminated disease (n = 16) was associated with inferior OS and EFS, while age ≥11 years and total resection were favorable factors for EFS. We observed 117 patients following total (n = 24) or subtotal/partial resection (n = 74), biopsy (n = 16), or radiologic diagnosis only (n = 3). Eleven patients were treated first with chemotherapy (n = 9) or irradiation (n = 2). Up to 20.8 years after diagnosis/initial intervention, 73/128 patients experienced one (n = 43) or up to six (n = 30) radiological/clinical disease progressions. Tumor resections were repeated in 36 patients (range, 2-6) and 47 patients required nonsurgical treatment (chemotherapy, n = 20; radiotherapy, n = 10; multiple treatment lines, n = 17). Long-term disease control for a median of 6.5 (range, 0.02-20) years was achieved in 73/77 patients following one (n = 57) or repeated (n = 16) resections, and in 35/47 patients after nonsurgical treatment. The majority of patients experienced disease progression, even after years. Multiple interventions were required for more than a third, yet multimodal treatment enabled long-term disease control. Molecular testing may reveal therapeutic targets.

8 May 2024 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
GNGunther Nussbaumer
Gunther Nussbaumer
MBMartin Benesch
Martin Benesch
YGYura Grabovska
Yura Grabovska
AMAlan Mackay
Alan Mackay
DCDavid Castel
David Castel
CKChristof Maria Kramm
Christof Maria Kramm
The term Gliomatosis cerebri (GC), a radiology-defined highly infiltrating diffuse glioma, has been abandoned since molecular GC-associated features have not been established yet. We conducted a multinational retrospective study of 104 children and adolescents with GC providing comprehensive clinical and (epi-)genetic characterization. Median overall survival (OS) was 15.5 months (interquartile range, 10.9–27.7) with a 2-years survival rate of 28%. Histopathological grading correlated significantly with median OS: CNS WHO grade II: 47.8 months (25.2–55.7); grade III: 15.9 months (11.4–26.3); grade IV: 10.4 months (8.8–14.4). By DNA methylation profiling (n=49), most tumors were classified as pediatric-type diffuse high-grade glioma (pedHGG), H3-/IDH-wildtype (n=31/49, 63.3%) with enriched subclasses pedHGG_RTK2 (n=19), pedHGG_A/B (n=6), and pedHGG_MYCN (n=5), but only one pedHGG_RTK1 case. Within the pedHGG, H3-/IDH-wildtype subgroup, recurrent alterations in EGFR (n=10) and BCOR (n=9) were identified. Additionally, we observed structural aberrations in chromosome 6 in 16/49 tumors (32.7%) across tumor types. In the pedHGG, H3-/IDH-wildtype subgroup TP53 alterations had a significant negative effect on OS. Contrary to previous studies, our representative pediatric GC study provides evidence that GC has a strong predilection to arise on the background of specific molecular features (especially pedHGG_RTK2, pedHGG_A/B, EGFR and BCOR mutations, chromosome 6 rearrangements).

22 September 2022 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
MBM. Benesch
M. Benesch
TPT. Perwein
T. Perwein
GAG. Apfaltrer
G. Apfaltrer
TLThorsten Langer
Thorsten Langer
ANAlexander Neumann
Alexander Neumann
BBBrigitte Bison
Brigitte Bison
BACKGROUND AND PURPOSE: Diffuse glioneuronal tumor with oligodendroglioma-like features and nuclear clusters (DGONC) is a new, molecularly defined glioneuronal CNS tumor type. The objective of the present study was to describe MR imaging and clinical characteristics of patients with DGONC. MATERIALS AND METHODS: Preoperative MR images of 9 patients with DGONC (median age at diagnosis, 9.9 years; range, 4.2–21.8 years) were reviewed. RESULTS: All tumors were located superficially in the frontal/temporal lobes and sharply delineated, displaying little mass effect. Near the circle of Willis, the tumors encompassed the arteries. All except one demonstrated characteristics of low-to-intermediate aggressiveness with high-to-intermediate T2WI and ADC signals and bone remodeling. Most tumors (n = 7) showed a homogeneous ground-glass aspect on T2-weighted and FLAIR images. On the basis of the original histopathologic diagnosis, 6 patients received postsurgical chemo-/radiotherapy, 2 were irradiated after surgery, and 1 patient underwent tumor resection only. At a median follow-up of 61 months (range, 10–154 months), 6 patients were alive in a first complete remission and 2 with stable disease 10 and 21 months after diagnosis. The only patient with progressive disease was lost to follow-up. Five-year overall and event-free survival was 100% and 86±13%, respectively. CONCLUSIONS: This case series presents radiomorphologic characteristics highly predictive of DGONC that contrast with the typical aspects of the original histopathologic diagnoses. This presentation underlines the definition of DGONC as a separate entity, from a clinical perspective. Complete resection may be favorable for long-term disease control in patients with DGONC. The efficacy of nonsurgical treatment modalities should be evaluated in larger series.

1 February 2023 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
TPThomas Perwein
Thomas Perwein
BGBarbara Giese
Barbara Giese
GNGunther Nussbaumer
Gunther Nussbaumer
ABAndré O. von Bueren
André O. von Bueren
MBMiriam van Buiren
Miriam van Buiren
CKChristof Maria Kramm
Christof Maria Kramm
Purpose: As there is no standard of care treatment for recurrent/progressing pediatric high-grade gliomas (pHGG), we aimed to gain an overview of different treatment strategies. Methods: In a web-based questionnaire, members of the SIOPE-BTG and the GPOH were surveyed on therapeutic options in four case scenarios (children/adolescents with recurrent/progressing HGG). Results: 139 clinicians with experience in pediatric neuro-oncology from 22 European countries participated in the survey. Most respondents preferred further oncological treatment in three out of four cases and chose palliative care in one case with marked symptoms. Depending on the case, 8–92% would initiate a re-resection (preferably hemispheric pHGG), combined with molecular diagnostics. Throughout all case scenarios, 55–77% recommended (re-)irradiation, preferably local radiotherapy > 20 Gy. Most respondents would participate in clinical trials and use targeted therapy (79–99%), depending on molecular genetic findings (BRAF alterations: BRAF/MEK inhibitor, 64–88%; EGFR overexpression: anti-EGFR treatment, 46%; CDKN2A deletion: CDK inhibitor, 18%; SMARCB1 deletion: EZH2 inhibitor, 12%). 31–72% would administer chemotherapy (CCNU, 17%; PCV, 8%; temozolomide, 19%; oral etoposide/trofosfamide, 8%), and 20–69% proposed immunotherapy (checkpoint inhibitors, 30%; tumor vaccines, 16%). Depending on the individual case, respondents would also include bevacizumab (6–18%), HDAC inhibitors (4–15%), tumor-treating fields (1–26%), and intraventricular chemotherapy (4–24%). Conclusion: In each case, experts would combine conventional multimodal treatment concepts, including re-irradiation, with targeted therapy based on molecular genetic findings. International cooperative trials combining a (chemo-)therapy backbone with targeted therapy approaches for defined subgroups may help to gain valid clinical data and improve treatment in pediatric patients with recurrent/progressing HGG.

8 February 2024 in EJC Paediatric Oncology
Verified
Journal Article
Open access
MEMoatasem El-Ayadi
Moatasem El-Ayadi
KDKyra Druivenga
Kyra Druivenga
TPThomas Perwein
Thomas Perwein
GNGunther Nussbaumer
Gunther Nussbaumer
FSFilippo Spreafico
Filippo Spreafico
CKChristof M. Kramm
Christof M. Kramm

9 February 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
PDF file
TPThomas Perwein
Thomas Perwein
HLHerwig Lackner
Herwig Lackner
GEGeorg Ebetsberger‐Dachs
Georg Ebetsberger‐Dachs
CBChristine Beham‐Schmid
Christine Beham‐Schmid
KZKlara Zach
Klara Zach
TGthe Austrian Society of Pediatric Hematology and Oncology and the Austrian Berlin‐Frankfurt‐Münster (BFM) Study Group
the Austrian Society of Pediatric Hematology and Oncology and the Austrian Berlin‐Frankfurt‐Münster (BFM) Study Group
Background: Data on management of gray zone lymphoma (GZL) in children and adolescents are scarce.Procedure: This retrospective study assessed clinical characteristics and outcome in six Austrian patients with GZL less than 18 years of age (male‐to‐female ratio: 1:1; median age: 15.8 years).Results: Two patients each had a classical Hodgkin lymphoma (cHL)‐like and composite GZL subtype, and one patient each had a large B‐cell non‐Hodgkin lymphoma (LBCL)‐like and sequential GZL subtype. All had advanced disease with mediastinal and extranodal involvement. Five patients received an LBCL‐ and one patient a cHL‐directed polychemotherapy ± radiotherapy. Out of the former patients, three survived, including two who relapsed and underwent high‐dose chemotherapy with autologous stem cell rescue. The latter patient survived.Conclusions: GZL remains a diagnostic and therapeutic challenge, necessitating the development of novel treatment concepts performed in a prospective setting.